• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aziyo Biologics Inc.

    2/14/24 4:51:40 PM ET
    $AZYO
    Medical Specialities
    Health Care
    Get the next $AZYO alert in real time by email
    SC 13G 1 tm243309d27_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    ELUTIA INC.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    05479K106

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

     

    CUSIP NO. 05479K106   Page 2 of 7

     

    CUSIP No.  05479K106
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,912,776
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,912,776
    (9) Aggregate amount beneficially owned by each reporting person 1,912,776
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO. 05479K106   Page 3 of 7

     

    CUSIP No.  05479K106
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,912,776
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,912,776
    (9) Aggregate amount beneficially owned by each reporting person 1,912,776
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO. 05479K106   Page 4 of 7

     

    CUSIP No.  05479K106
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,912,776
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,912,776
    (9) Aggregate amount beneficially owned by each reporting person 1,912,776
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      ELUTIA INC. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      12510 PROSPERITY DRIVE SUITE 370, SILVER SPRING, MD 20904
       
    Item 2(a). Name of Person Filing
       
      Nantahala Capital Management, LLC (“Nantahala”)
    Wilmot B. Harkey
    Daniel Mack (together the “Reporting Persons”)
       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
      130 Main St. 2nd Floor
    New Canaan, CT 06840  
       
    Item 2(c). Citizenship:
       
      Nantahala is a Massachusetts limited liability company.
    Each of Messrs. Harkey and Mack is a citizen of the United States of America.
       
    Item 2(d). Title of Class of Securities:  
       
      Class A Common Stock, par value $0.001 per share (the “Shares”).  

     

     

     

     

    CUSIP NO. 05479K106   Page 5 of 7

     

     

    Item 2(e).

    CUSIP Number:
     

     

    05479K106

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

    Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 1,912,776 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 1,912,776 Shares includes 262,776 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 9.9% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed November 14, 2023, there were 18,884,146 Shares outstanding in addition to the 262,776 Shares issuable upon the exercise of the warrants.

       

     

     

     

     

    CUSIP NO. 05479K106   Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
           
      (ii) Shared power to vote or to direct the vote 1,912,776
           
      (iii) Sole power to dispose or to direct the disposition of 0
           
      (iv) Shared power to dispose or to direct the disposition of 1,912,776
           
     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
           
      (ii) Shared power to vote or to direct the vote 1,912,776
           
      (iii) Sole power to dispose or to direct the disposition of 0
           
      (iv) Shared power to dispose or to direct the disposition of 1,912,776
           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

     

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP NO. 05479K106   Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By: /s/ Taki Vasilakis
        Taki Vasilakis
        Chief Compliance Officer
       
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $AZYO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AZYO

    DatePrice TargetRatingAnalyst
    3/4/2022$15.00 → $13.00Outperform
    Cowen & Co.
    More analyst ratings

    $AZYO
    SEC Filings

    See more
    • SEC Form 424B3 filed by Aziyo Biologics Inc.

      424B3 - ELUTIA INC. (0001708527) (Filer)

      2/14/24 4:40:48 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - ELUTIA INC. (0001708527) (Filer)

      2/2/24 4:30:21 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Aziyo Biologics Inc.

      S-8 - ELUTIA INC. (0001708527) (Filer)

      1/25/24 4:56:17 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen & Co. reiterated coverage on Aziyo Biologics with a new price target

      Cowen & Co. reiterated coverage of Aziyo Biologics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously

      3/4/22 9:16:21 AM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference

      SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET. A live webcast of the presentation can be accessed by visiting the Company's Events & Presentations webpage or by clicking here. A replay will be available on the Company's website following the event. Institutional investors interested in meeting with management during the conference may reach out

      9/8/23 8:30:00 AM ET
      $AZYO
      $ELUT
      Medical Specialities
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices

      – Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective today, September 6, 2023. The Company's stock will begin trading on Nasdaq under the new ticker symbol "ELUT" on September 7, 2023. "We are excited to introduce Elutia, where we exist to humanize medicine by pioneering drug-eluting biomatrix or DEB technology," said Dr. Randy Mills

      9/6/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

      Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs. The report, titled "Rehabilitation of an Existing Device Implant Pocket Using a Biolog

      8/30/23 8:30:00 AM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mills C Randal

      4 - ELUTIA INC. (0001708527) (Issuer)

      2/2/24 4:38:14 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Ferguson Matthew

      4 - ELUTIA INC. (0001708527) (Issuer)

      2/2/24 4:35:23 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Williams Michelle Leroux

      4 - ELUTIA INC. (0001708527) (Issuer)

      2/2/24 4:32:46 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aziyo Biologics Inc.

      SC 13G - ELUTIA INC. (0001708527) (Subject)

      2/14/24 4:51:40 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Aziyo Biologics Inc. (Amendment)

      SC 13G/A - ELUTIA INC. (0001708527) (Subject)

      2/7/24 6:55:18 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Aziyo Biologics Inc. (Amendment)

      SC 13D/A - ELUTIA INC. (0001708527) (Subject)

      1/9/24 4:17:26 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of Directors

      SILVER SPRING, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022. His appointment brings the company's Board of Directors to six members. "David's impressive commercial expertise was vital in guiding some of the world's largest and most-well respected biopharmaceutical companies in achieving their growth milestones," said Dr. Randy Mills, Chief Executive Officer of Aziyo Biologics. "We specifically sought a Board member, like David, whose deep industry insights and busi

      10/24/22 8:00:00 AM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific Officer

      SILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer. "Aziyo strives to have the best products in the markets in which we choose to compete, and Dr. Williams has the expertise and leadership to help us deliver just that," said Dr. Randy Mills, Chief Executive Officer. "Michelle has been a thought leader in regenerative medicine for two decades. She has a track record of consistently developing commercially successful products, including Osteocel®, the world's first stem cell product with cumulative sales of

      8/26/22 9:00:00 AM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Appoints Peter G. Edwards as General Counsel

      SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel. "We are delighted to welcome such a strong and experienced leader as Peter to our executive team," said Ron Lloyd, President and Chief Executive Officer of Aziyo. "We expect his deep experience serving as general counsel to high growth companies, particularly in the healthcare sector, will prove to be invaluable as we head into our next phase of growth. We have

      8/31/21 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highcape Capital, Llc bought 2,837,128 shares (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      10/5/23 4:50:43 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Highcape Capital, L.P. bought 2,837,128 shares (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      10/5/23 4:43:44 PM ET
      $AZYO
      Medical Specialities
      Health Care

    $AZYO
    Financials

    Live finance-specific insights

    See more
    • Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company

      Negotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June 30, 2023. "Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company

      8/14/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

      SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID:

      7/31/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care
    • Aziyo Biologics Reports Highest Sales and Gross Profit in Company History

      - All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Business Highlights: Net sales rose 14% compared to the prior-year period, to a record $13.1 million for first quarter 2023.Gross margin increased 11 percentage points year-over-year to 49%.Signed a partnership with LeMaitre Vascular to distribute Aziyo'

      5/10/23 4:05:00 PM ET
      $AZYO
      Medical Specialities
      Health Care